Case Studies

lifescience
Modelling HIV Reverse Transcriptase

High performance computing was used to investigate the effects of resistance mutations within a crucial enzyme of Human Immunodeficiency Virus (HIV) towards the antiviral drug Nevirapine.

Human Immunodeficiency Virus (HIV) currently affects approximately 40 million people worldwide and although a number of antiviral drugs are available for treatment, the virus often develops resistance to these medications.

Changing to alternate drugs can often lead to further resistance until no drug choices remain for the patient, and thus can not be used as a long term strategy to overcome this issue.As it is difficult to predict what resistance mutations will arise upon starting a new antiviral treatment, it is desirable to have a model system upon which to test the existing range of drugs to assess which drug is most suitable to treat that particular strain of the virus.

Further Information

For further information regarding this project or for information on VPAC’s life science solutions and services, please contact VPAC at lifesciences@vpac.org or phone +61 3 9925 4645, or visit www.vpac.org.

Modelling download